Beximco Pharma provides access to affordable version

The Beximco Pharmaceuticals will make available 'Triko', its brand medicine for generic version of Trikafta used to treat Cystic fibrosis (CF), at an affordable cost from spring 2026. CF is a life-threatening genetic disorder with very low life expectancy, says a press release.

Triko will cost US$ 12,750 per year for an adult patient while, for a child, it will cost US$6,375 per year.

The cost of Trikafta, a triple combination therapy for CF containing elexacaftor, tezacaftor and ivacaftor, produced by the US-based Vertex Pharmaceuticals is US $370,000 for a child per year. Unfortunately, very few patients can have access to this blockbuster drug due to exorbitant cost.

On this grim backdrop, a group of mothers whose children are living with CF have launched a community-run buyers' club to help patients around the world access to BeximcoPharma's 'Triko'. The families unveiled the news on October 23, at the North American Cystic Fibrosis Conference (NACFC) in Seattle, Washington.

Gayle Pledger, a senior organiser for Just Treatment who leads the global Right to Breathe campaign, also a CF mother from the UK, announced the launch of the BeximcoPharma's generic Triko at NACFC Said, "This is a historic moment - patients, families and allies have come together to build the solution that the global CF community has been waiting for. We've watched children suffer and die while a treatment sat on the shelf, priced out of reach. Today, that changes, we've proven that patient power can change what billion dollar corporations refuse to."

Beximco Pharmaceuticals Chief Operation Officer, Rabbur Reza, said, "At BeximcoPharma, we always strive to address patients' unmet medical needs, especially in therapy areas with very limited access. A central tenet of our business philosophy is responding to the evolving needs of patients to make a meaningful impact on the quality of their lives. We understand that access to medicine for rare diseases, like CF, is restricted due to a limited number of treatment options which are prohibitively expensive. We believe our much affordable generic version of Trikafta will have a transformative impact on thousands of patients living with CF who are currently deprived of treatment due to the significant cost burden."